Nonalcoholic fatty liver disease: Molecular pathways and therapeutic strategies

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Huang, Yue Ye ^a   Gusdon, Aaron M ^c   Qu, Shen ^a,b  

^a TONGJI UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Molecular mechanisms; Nonalcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA DEXTRO RIBOFURANOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACYL COENZYME A DESATURASE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETAINE; BIGUANIDE DERIVATIVE; BILE ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABIS; CARNITINE PALMITOYLTRANSFERASE; COENZYME A; CURCUMIN; FARNESOID X RECEPTOR; FATTY ACID SYNTHASE; METFORMIN; PREGNANE X RECEPTOR; SILIBININ; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

APOPTOSIS; CELL METABOLISM; DRUG TARGETING; FATTY ACID OXIDATION; FATTY LIVER; GENE DELETION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; KETOGENESIS; LIPID PEROXIDATION; LIVER FIBROSIS; METABOLIC SYNDROME X; MITOCHONDRION; MOLECULAR BIOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; REVIEW;

CURCUMIN; FATTY ACID SYNTHASE, TYPE I; FATTY LIVER; FIBRIC ACIDS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIVER; MITOCHONDRIA; PEROXISOMES; PPAR GAMMA; PROTECTIVE AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; THIAZOLIDINEDIONES;

EID: 84887064874     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-171     Document Type: Review

References (115)

1. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Zhou J, et al. Gastroenterology 2008 134 2 556 567 10.1053/j.gastro.2007.11.037 18242221 (Pubitemid 351173049)
2. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Blumberg B, et al. Genes Dev 1998 12 20 3195 3205 10.1101/gad.12.20.3195 9784494 (Pubitemid 28496264)
3. CAR and PXR: the xenobiotic-sensing receptors. Timsit YE, Negishi M, Steroids 2007 72 3 231 246 10.1016/j.steroids.2006.12.006 17284330 (Pubitemid 46273513)
4. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. Zhou J, et al. J Biol Chem 2006 281 21 15013 15020 10.1074/jbc.M511116200 16556603 (Pubitemid 43855205)
5. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Moreau A, et al. Hepatology 2009 49 6 2068 2079 10.1002/hep.22907 19437491
6. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M, Nature 2004 432 7020 1027 1032 10.1038/nature03047 15616563 (Pubitemid 40052233)
7. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. Nakamura K, Moore R, Negishi M, Sueyoshi T, J Biol Chem 2007 282 13 9768 9776 10.1074/jbc.M610072200 17267396 (Pubitemid 47104600)
8. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Valenti L, et al. Diabetes 2008 57 5 1355 1362 10.2337/db07-0714 18316359
9. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Kodama S, Koike C, Negishi M, Yamamoto Y, Mol Cell Biol 2004 24 18 7931 7940 10.1128/MCB.24.18. 7931-7940.2004 15340055 (Pubitemid 39167443)
10. Bile acids: natural ligands for an orphan nuclear receptor. Parks DJ, et al. Science 1999 284 5418 1365 1368 10.1126/science.284.5418.1365 10334993 (Pubitemid 29289664)
11. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Downes M, et al. Mol Cell 2003 11 4 1079 1092 10.1016/S1097- 2765(03)00104-7 12718892 (Pubitemid 36566328)
12. Targeting bile-acid signalling for metabolic diseases. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K, Nat Rev Drug Discov 2008 7 8 678 693 10.1038/nrd2619 18670431
13. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Musso G, Gambino R, Cassader M, Annu Rev Med 2010 61 375 392 10.1146/annurev.med.60.101107.134820 20059344
14. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Sinal CJ, et al. Cell 2000 102 6 731 744 10.1016/S0092-8674(00)00062-3 11030617
15. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. Kong B, Luyendyk JP, Tawfik O, Guo GL, J Pharmacol Exp Ther 2009 328 1 116 122 10.1124/jpet.108.144600 18948497
16. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA, Genes Dev 2004 18 2 157 169 10.1101/gad.1138104 14729567 (Pubitemid 38141784)
17. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Claudel T, et al. Gastroenterology 2003 125 2 544 555 10.1016/S0016-5085(03)00896-5 12891557 (Pubitemid 36929436)
18. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. Yamagata K, et al. J Biol Chem 2004 279 22 23158 23165 10.1074/jbc.M314322200 15047713 (Pubitemid 38685621)
19. Farnesoid X receptor is essential for normal glucose homeostasis. Ma K, Saha PK, Chan L, Moore DD, J Clin Invest 2006 116 4 1102 1109 10.1172/JCI25604 16557297
20. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Inagaki T, et al. Proc Natl Acad Sci USA 2006 103 10 3920 3925 10.1073/pnas.0509592103 16473946 (Pubitemid 43376656)
21. Identification of a physiologically relevant endogenous ligand for Pplpha in liver. Chakravarthy MV, et al. Cell 2009 138 3 476 488 10.1016/j.cell.2009. 05.036 19646743
22. Role of histone methylation and demethylation in adipogenesis and obesity. Okamura M, Inagaki T, Tanaka T, Sakai J, Organogenesis 2010 6 1 24 32 10.4161/org.6.1.11121 20592862
23. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Nissen SE, Wolski K, Arch Intern Med 2010 170 14 1191 1201 20656674
24. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? Dongiovanni P, Valenti L, PPAR Research 2013 2013 452061 23431284
25. Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. Sahebkar A, DNA Cell Biol 2013 32 4 188 198 10.1089/dna.2012.1947 23448101
26. Association between the Pro12Ala polymorphism of PPAR-gamma gene and the non-alcoholic fatty liver disease: a meta-analysis. Wang J, et al. Gene 2013 528 2 328 334 10.1016/j.gene.2013.07.014 23891820
27. Biogenesis of peroxisomes. Lazarow PB, Fujiki Y, Annu Rev Cell Biol 1985 1 489 530 10.1146/annurev.cb.01.110185.002421 3916321
28. Lipid metabolism in peroxisomes in relation to human disease. Wanders RJ, Tager JM, Mol Aspects Med 1998 19 2 69 154 9827430 (Pubitemid 28502311)
29. Biochemistry of mammalian peroxisomes revisited. Wanders RJ, Waterham HR, Annu Rev Biochem 2006 75 295 332 10.1146/annurev.biochem.74.082803.133329 16756494 (Pubitemid 44118035)
30. Clofibrate-inducible, 28-kDa peroxisomal integral membrane protein is encoded by PEX11. Abe I, Okumoto K, Tamura S, Fujiki Y, FEBS Lett 1998 431 3 468 472 10.1016/S0014-5793(98)00815-1 9714566 (Pubitemid 28352413)
31. Pex11pbeta-mediated growth and division of mammalian peroxisomes follows a maturation pathway. Delille HK, et al. J Cell Sci 2010 123 Pt 16 2750 2762 20647371
32. PEX11 family members are membrane elongation factors that coordinate peroxisome proliferation and maintenance. Koch J, et al. J Cell Sci 2010 123 Pt 19 3389 3400 20826455
33. Pmp27 promotes peroxisomal proliferation. Marshall PA, et al. J Cell Biol 1995 129 2 345 355 10.1083/jcb.129.2.345 7721939
34. Expression of PEX11beta mediates peroxisome proliferation in the absence of extracellular stimuli. Schrader M, et al. J Biol Chem 1998 273 45 29607 29614 10.1074/jbc.273.45.29607 9792670 (Pubitemid 28509969)
35. PEX11alpha is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated peroxisome proliferation. Li X, et al. Mol Cell Biol 2002 22 23 8226 8240 10.1128/MCB.22.23.8226-8240.2002 12417726 (Pubitemid 35304056)
36. Pex11alpha deficiency impairs peroxisome elongation and division and contributes to nonalcoholic fatty liver in mice. Weng H, et al. Am J Physiol Endocrinol Metab 2013 304 2 187 E196 10.1152/ajpendo.00425.2012 23169785
37. A pivotal role for p53: balancing aerobic respiration and glycolysis. Ma W, Sung HJ, Park JY, Matoba S, Hwang PM, J Bioenerg Biomembr 2007 39 3 243 246 10.1007/s10863-007-9083-0 17551815 (Pubitemid 47619376)
38. p53 involvement in the pathogenesis of fatty liver disease. Yahagi N, et al. J Biol Chem 2004 279 20 20571 20575 10.1074/jbc.M400884200 14985341 (Pubitemid 38656450)
39. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. Farrell GC, et al. J Gastroenterol Hepatol 2009 24 3 443 452 10.1111/j.1440-1746.2009.05785.x 19226377
40. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. Derdak Z, et al. J Hepatol 2013 58 4 785 791 10.1016/j.jhep.2012.11.042 23211317
41. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. Castro RE, et al. J Hepatol 2013 58 1 119 125 10.1016/j.jhep.2012.08.008 22902550
42. Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice. Pommier AJ, et al. PLoS Genet 2013 9 5 1003483 10.1371/journal.pgen.1003483 23675307
43. LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor. Zelcer N, Hong C, Boyadjian R, Tontonoz P, Science 2009 325 5936 100 104 10.1126/science.1168974 19520913
44. Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress. Suckling K, Expert Opin Investig Drugs 2008 17 5 615 618 10.1517/13543784.17.5.615 18447589 (Pubitemid 351843608)
45. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Berkenstam A, et al. Proc Natl Acad Sci USA 2008 105 2 663 667 10.1073/pnas.0705286104 18160532 (Pubitemid 351171765)
46. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Cable EE, et al. Hepatology 2009 49 2 407 417 10.1002/hep.22572 19072834
47. The role of triiodothyronine-induced substrate cycles in the hepatic response to overnutrition: thyroid hormone as an antioxidant. Grant N, Med Hypotheses 2007 68 3 641 649 10.1016/j.mehy.2006.07.045 17023119 (Pubitemid 46037960)
48. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Hardie DG, Genes Dev 2011 25 18 1895 1908 10.1101/gad.17420111 21937710
49. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). Barnes K, et al. J Cell Sci 2002 115 Pt 11 2433 2442 12006627 (Pubitemid 34752985)
50. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Marsin AS, et al. Current Biology: CB 2000 10 20 1247 1255 10.1016/S0960-9822(00)00742-9 11069105
51. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Mihaylova MM, et al. Cell 2011 145 4 607 621 10.1016/j.cell.2011.03.043 21565617
52. The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Jorgensen SB, et al. Diabetes 2004 53 12 3074 3081 10.2337/diabetes.53.12.3074 15561936 (Pubitemid 39564481)
53. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Koo SH, et al. Nature 2005 437 7062 1109 1111 10.1038/nature03967 16148943 (Pubitemid 41509342)
54. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Foretz M, et al. Diabetes 2005 54 5 1331 1339 10.2337/diabetes.54.5.1331 15855317 (Pubitemid 40586661)
55. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Jager S, Handschin C, St-Pierre J, Spiegelman BM, Proc Natl Acad Sci USA 2007 104 29 12017 12022 10.1073/pnas.0705070104 17609368 (Pubitemid 47185622)
56. AMPK and PPARdelta agonists are exercise mimetics. Narkar VA, et al. Cell 2008 134 3 405 415 10.1016/j.cell.2008.06.051 18674809
57. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. Jorgensen SB, et al. FASEB J 2005 19 9 1146 1148 15878932 (Pubitemid 40946446)
58. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Zhang W, et al. Clin Exp Pharmacol Physiol 2012 39 12 1026 1033 10.1111/1440-1681.12020 23127227
59. Role of AMP-activated protein kinase in mechanism of metformin action. Zhou G, et al. J Clin Invest 2001 108 8 1167 1174 11602624 (Pubitemid 32995375)
60. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. Zang M, et al. J Biol Chem 2004 279 46 47898 47905 10.1074/jbc.M408149200 15371448 (Pubitemid 39540941)
61. Pioglitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain. Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, Munoz-Yague T, Solis-Herruzo JA, BMC Biol 2013 11 88 10.1186/1741-7007-11-88 23915000
62. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Divakaruni AS, et al. Proc Natl Acad Sci USA 2013 110 14 5422 5427 10.1073/pnas.1303360110 23513224
63. Resveratrol improves health and survival of mice on a high-calorie diet. Baur JA, et al. Nature 2006 444 7117 337 342 10.1038/nature05354 17086191 (Pubitemid 44764104)
64. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Hwang JT, et al. Cancer Lett 2007 247 1 115 121 10.1016/j.canlet.2006. 03.030 16797120 (Pubitemid 46001507)
65. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. Hou X, et al. J Biol Chem 2008 283 29 20015 20026 10.1074/jbc.M802187200 18482975
66. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. Collins QF, et al. J Biol Chem 2007 282 41 30143 30149 10.1074/jbc.M702390200 17724029 (Pubitemid 350035266)
67. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Gledhill JR, Montgomery MG, Leslie AG, Walker JE, Proc Natl Acad Sci USA 2007 104 34 13632 13637 10.1073/pnas.0706290104 17698806 (Pubitemid 350003372)
68. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. Valenti D, et al. Biochimica et Piophysica Acta 2013 1832 12 2085 2096 10.1016/j.bbadis.2013.07.014
69. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Bergeron R, et al. Diabetes 2001 50 5 1076 1082 10.2337/diabetes.50.5.1076 11334411 (Pubitemid 32374538)
70. Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. Taylor EB, et al. J Biol Chem 2008 283 15 9787 9796 10.1074/jbc.M708839200 18276596
71. Inhibition of glucokinase translocation by AMP-activated protein kinase is associated with phosphorylation of both GKRP and 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase. Mukhtar MH, et al. Am J Physiol Regul Integr Comp Physiol 2008 294 3 766 R774 10.1152/ajpregu.00593.2007 18199594 (Pubitemid 351346952)
72. AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Guigas B, et al. Biochem J 2007 404 3 499 507 10.1042/BJ20070105 17324122 (Pubitemid 46953924)
73. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D, Biochem J 2007 403 1 139 148 10.1042/BJ20061520 17147517 (Pubitemid 46569875)
74. Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators. Guigas B, et al. IUBMB life 2009 61 1 18 26 10.1002/iub.135 18798311
75. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Song Z, et al. Am J Physiol Gastrointest Liver Physiol 2007 293 4 894 G902 10.1152/ajpgi.00133.2007 17702954 (Pubitemid 47610419)
76. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Lee WJ, et al. Biochem Biophys Res Commun 2005 332 3 885 891 10.1016/j.bbrc.2005.05.035 15913551 (Pubitemid 40745196)
77. Yi X, Pashaj A, Xia M, Moreau R, Reversal of obesity-induced hypertriglyceridemia by (R)-alpha-lipoic acid in ZDF (fa/fa) rats. Biochemical and biophysical research communications 2013 http://www.ncbi.nlm.nih.gov/pubmed/ term=Reversal+of+obesity-induced+hypertriglyceridemia+by+(R)-alpha- lipoic+acid+in+ZDF+(fa%2Ffa)+rats
78. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Yamauchi T, et al. Nat Med 2007 13 3 332 339 10.1038/nm1557 17268472 (Pubitemid 46376688)
79. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Andreelli F, et al. Endocrinology 2006 147 5 2432 2441 10.1210/en.2005-0898 16455782
80. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. Xu A, et al. J Clin Invest 2003 112 1 91 100 12840063 (Pubitemid 38056380)
81. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. McMahan RH, et al. J Biol Chem 2013 288 17 11761 11770 10.1074/jbc.M112.446575 23460643
82. Nrf2: A Potential Target for New Therapeutics in Liver Disease. Bataille AM, Manautou JE, Clin Pharmacol Ther 2012 92 3 340 348 10.1038/clpt.2012.110 22871994
83. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B, Hepatology 2013 58 4 1497 1507 10.1002/hep.26226 23299992
84. Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence? Garcia-Ruiz C, Baulies A, Mari M, Garcia-Roves PM, Fernandez-Checa JC, Free Radic Res 2013 47 11 854 868 10.3109/10715762.2013.830717 23915028
85. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Koliaki C, Roden M, l Cell Endocrinol 2013 379 1-2 35 42
86. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Fabbrini E, Sullivan S, Klein S, Hepatology 2010 51 2 679 689 10.1002/hep.23280 20041406
87. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. Tamura S, Shimomura I, J Clin Invest 2005 115 5 1139 1142 15864343 (Pubitemid 40629030)
88. Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose. Crescenzo R, et al. Eur J Nutr 2013 52 2 537 545 10.1007/s00394-012-0356-y 22543624
89. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats. Ciapaite J, et al. Biochim Biophys Acta 2011 1811 7-8 441 451 21621638
90. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Dasarathy S, et al. Eur J Gastroenterol Hepatol 2011 23 5 382 388 10.1097/MEG. 0b013e328345c8c7 21448070
91. Obesity and leptin resistance: distinguishing cause from effect. Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW, Trends Endocrinol Metab 2010 21 11 643 651 10.1016/j.tem.2010.08.002 20846876
92. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Dushay J, et al. Gastroenterology 2010 139 2 456 463 10.1053/j.gastro.2010.04.054 20451522
93. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Li H, et al. J Hepatol 2010 53 5 934 940 10.1016/j.jhep.2010.05.018 20675007
94. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Matthews VB, et al. Diabetologia 2010 53 11 2431 2441 10.1007/s00125-010-1865-y 20697689
95. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Takamura T, et al. Obesity 2008 16 12 2601 2609 10.1038/oby.2008.419 18846047
96. Regulation of hepatic fat and glucose oxidation in rats with lipid-induced hepatic insulin resistance. Alves TC, et al. Hepatology 2011 53 4 1175 1181 10.1002/hep.24170 21400553
97. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. Esposito E, et al. J Nutr 2009 139 5 905 911 10.3945/jn.108.101808 19321579
98. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Serviddio G, et al. Eur J Clin Invest 2008 38 4 245 252 10.1111/j.1365-2362.2008.01936.x 18339004 (Pubitemid 351389142)
99. Liver mitochondrial function and redox status in an experimental model of non-alcoholic fatty liver disease induced by monosodium L-glutamate in rats. Lazarin Mde O, et al. Exp Mol Pathol 2011 91 3 687 694 10.1016/j.yexmp.2011.07. 003 21821020
100. Regulation of hepatic mitochondrial metabolism in response to a high fat diet: a longitudinal study in rats. Flamment M, et al. J Physiol Biochem 2012 68 3 335 344 10.1007/s13105-012-0145-3 22278845
101. Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. Jiang Y, Zhang H, Dong LY, Wang D, An W, J Cell Biochem 2008 105 1 277 289 10.1002/jcb.21827 18543254
102. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B, J Hepatol 2011 54 4 773 794 10.1016/j.jhep.2010.11.006 21145849
103. Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity. Mingorance C, et al. PloS one 2012 7 3 34268 10.1371/journal.pone.0034268 22457831
104. Defective leptin-AMP-dependent kinase pathway induces nitric oxide release and contributes to mitochondrial dysfunction and obesity in ob/ob mice. Finocchietto PV, et al. Antioxid Redox Signal 2011 15 9 2395 2406 10.1089/ars.2010.3857 21529143
105. Role of mitochondria in non-alcoholic fatty liver disease. Pessayre D, J Gastroenterol Hepatol 2007 22 Suppl 1 20 S27 17567459
106. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. Mollica MP, et al. J Hepatol 2009 51 2 363 370 10.1016/j.jhep.2009.03.023 19464748
107. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Hancock CR, et al. Proc Natl Acad Sci USA 2008 105 22 7815 7820 10.1073/pnas.0802057105 18509063 (Pubitemid 351872721)
108. Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Ramirez-Tortosa MC, et al. Free Radic Biol Med 2009 47 7 924 931 10.1016/j.freeradbiomed.2009.06.015 19539747
109. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. Serviddio G, et al. J Pharmacol Exp Ther 2010 332 3 922 932 10.1124/jpet.109.161612 20008062
110. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Patumraj S, Klaikeaw N, J Med Assoc Thai 2007 90 4 788 797 17487136
111. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hezode C, et al. Hepatology 2005 42 1 63 71 10.1002/hep.20733 15892090 (Pubitemid 40911312)
112. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. Munoz-Luque J, et al. J Pharmacol Exp Ther 2008 324 2 475 483 18029545 (Pubitemid 351185849)
113. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Teixeira-Clerc F, et al. Nat Med 2006 12 6 671 676 10.1038/nm1421 16715087 (Pubitemid 43865236)
114. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A, Diabetes Care 2008 31 Suppl 2 229 S240 18227491
115. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Janero DR, Lindsley L, Vemuri VK, Makriyannis A, Expert Opinion on Drug Discovery 2011 6 10 995 1025 10.1517/17460441.2011.608063 22646861